Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Bodei

Showing results (51-60 of 184) with videos related to

Pageof 19
Sort By:
Nature Reviews. Clinical Oncology|June 21, 2022
Radiotheranostics in oncology: current challenges and emerging opportunitiesLisa Bodei, Ken Herrmann, Heiko Schöder, et al.
Seminars in Nuclear Medicine|April 13, 2016
Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic CancerLisa Bodei, Dik J Kwekkeboom, Mark Kidd, et al.
Neuroendocrinology|October 11, 2014
Neuroendocrine tumor biomarkers: current status and perspectivesIrvin M Modlin, Kjell Oberg, Andrew Taylor, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 20, 2004
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumoursLisa Bodei, Marta Cremonesi, Chiara Grana, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 24, 2008
EANM procedure guideline for treatment of refractory metastatic bone painLisa Bodei, Marnix Lam, Carlo Chiesa, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 23, 2014
The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see foreverLisa Bodei, Mark Kidd, Vikas Prasad, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2024
Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor PatientsJonathan R Strosberg, Taymeyah Al-Toubah, Ghassan El-Haddad, et al.
Clinical Nuclear Medicine|October 9, 2023
A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate CancerAndrew L Laccetti, Lisa Bodei, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 4, 2019
Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of PrometheusLisa Bodei, Ken Herrmann, Richard P Baum, et al.
AJR. American Journal of Roentgenology|January 5, 2022
Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response-<i>AJR</i> Expert Panel Narrative ReviewSamuel J Galgano, Amir Iravani, Lisa Bodei, et al.
Pageof 19

Showing results (51-60 of 184) with videos related to

Sort By:
Pageof 19
Nature Reviews. Clinical Oncology|June 21, 2022
Radiotheranostics in oncology: current challenges and emerging opportunitiesLisa Bodei, Ken Herrmann, Heiko Schöder, et al.
Seminars in Nuclear Medicine|April 13, 2016
Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic CancerLisa Bodei, Dik J Kwekkeboom, Mark Kidd, et al.
Neuroendocrinology|October 11, 2014
Neuroendocrine tumor biomarkers: current status and perspectivesIrvin M Modlin, Kjell Oberg, Andrew Taylor, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 20, 2004
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumoursLisa Bodei, Marta Cremonesi, Chiara Grana, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 24, 2008
EANM procedure guideline for treatment of refractory metastatic bone painLisa Bodei, Marnix Lam, Carlo Chiesa, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 23, 2014
The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see foreverLisa Bodei, Mark Kidd, Vikas Prasad, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2024
Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor PatientsJonathan R Strosberg, Taymeyah Al-Toubah, Ghassan El-Haddad, et al.
Clinical Nuclear Medicine|October 9, 2023
A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate CancerAndrew L Laccetti, Lisa Bodei, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 4, 2019
Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of PrometheusLisa Bodei, Ken Herrmann, Richard P Baum, et al.
AJR. American Journal of Roentgenology|January 5, 2022
Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response-<i>AJR</i> Expert Panel Narrative ReviewSamuel J Galgano, Amir Iravani, Lisa Bodei, et al.
Pageof 19